In addition, pre-treatment with lycopene (5, 10, and 20 mg/kg) has a protective role in a rat model of non-alcoholic fatty liver disease through lowering the liver enzymes levels, like aspartate transaminase (AST), alanine transaminase (ALT), LDL, free fatty acid, and MDA. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.